Using hearing aids may slow cognitive decline in some older adults with hearing loss, potentially lowering dementia risk. However, current evidence does not show that hearing aids prevent dementia for everyone. Cognitive decline means worsening memory, attention, or thinking ability over time; it is not the same as a dementia diagnosis. The World Health Organization's 2026 guidance describes dementia-risk reduction as a possible additional benefit of treating hearing loss, not a guaranteed result.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the randomized trial found
- Why observational studies remain encouraging but uncertain
- Who might benefit most?
- Why association is not proof
- What should someone with hearing loss do now?
What the randomized trial found
The ACHIEVE trial provides the strongest evidence because it randomly assigned nearly 1,000 participants to a hearing intervention or health education. Participants were ages 70 to 84, had untreated hearing loss, and did not have dementia. Across the entire group, the hearing intervention did not significantly slow cognitive decline over three years, according to the National Institute on Aging's ACHIEVE summary.
This overall result does not support claiming that hearing aids protect every older adult from cognitive decline. The result differed in participants from a long-running heart-health cohort. This higher-risk subgroup experienced about 48% less cognitive decline with the hearing intervention than with health education, according to the 2025 ACHIEVE analysis in JAMA Otolaryngology–Head & Neck Surgery.
Why observational studies remain encouraging but uncertain
A 2024 Danish study followed 573,088 adults aged 50 or older. Hearing loss was associated with a 7% higher dementia risk, while risk was higher among people without hearing aids than among hearing-aid users. Compared with people without hearing loss, the reported hazard ratios were 1.20 without aids and 1.06 with aids, according to the Danish cohort report. A 2025 Framingham study found a larger association among participants younger than 70.
Those with hearing loss who reported using hearing aids had a 61% lower incidence of dementia over as long as 20 years than nonusers with hearing loss. No such association appeared among participants aged 70 or older. Other evidence is less favorable. A 2024 French study of adults aged 45 to 69 linked hearing loss with worse cognition, but hearing-aid users did not have significantly lower odds of cognitive impairment than participants with disabling untreated hearing loss.
Who might benefit most?
The favorable ACHIEVE subgroup entered the trial with more dementia-risk factors. Participants were older, had lower initial cognitive scores and educational attainment, and had more diabetes than the healthier trial participants. That profile suggests hearing treatment may have more cognitive value when someone already faces elevated risk.
It does not prove that any single factor predicts who will benefit, and the subgroup result should not automatically be applied to healthier older adults. Age alone also cannot provide a reliable cutoff. ACHIEVE found a benefit in a higher-risk group aged 70 to 84, while Framingham found an association below age 70 but not at older ages. These studies used different designs and measured different populations.
Why association is not proof
Observational research can reveal patterns, but it cannot show that hearing aids caused a lower dementia rate. People who obtain hearing aids may differ from nonusers in health-care access, socioeconomic circumstances, hearing-loss severity, or other unmeasured ways. The Framingham analysis had another limitation: participants reported hearing-aid use only as "yes" or "no." That measure did not capture details that could help explain the observed association.
The randomized ACHIEVE trial offers stronger evidence about cause and effect. Yet its overall result was neutral, and its encouraging result came from a particular higher-risk subgroup. Together, these findings support cautious optimism rather than a dementia-prevention claim.
What should someone with hearing loss do now?
Identify and treat hearing loss for its established communication and quality-of-life benefits. Consider any possible reduction in cognitive decline or dementia risk an added benefit that remains uncertain. Practical next steps include:.
- Arrange a hearing assessment if you suspect hearing loss.
- Discuss hearing-treatment options and goals with a hearing-care provider.
- Ask how age, cognitive health, diabetes, and other personal factors affect the relevance of current evidence.
- Choose hearing treatment to address hearing loss, without treating it as a guarantee against dementia.
